Asthma Clinical Trials

Find Asthma Clinical Trials Near You

Understanding the Impact of Early-life RSV Infections on Infant Immunity and Long-term Health

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (\>6-9 months) in infancy.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 6 months
Healthy Volunteers: t
View:

• Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.

Locations
Other Locations
Canada
BC Women's Hospital and Health Centre
RECRUITING
Vancouver
Contact Information
Primary
Pascal Lavoie, MDCM PhD FRCPC
plavoie@bcchr.ca
604-875-2135
Backup
Allison Watts, PhD
awatts@bcchr.ca
604-875-2000
Time Frame
Start Date: 2026-01-15
Estimated Completion Date: 2029-12-01
Participants
Target number of participants: 300
Treatments
Fall group/cohort
Infants exposed to RSV \<4 months of age (born September-November)
Spring group/cohort
Infants exposed to RSV \>6-9 months of age (born April-June)
Related Therapeutic Areas
Sponsors
Leads: University of British Columbia

This content was sourced from clinicaltrials.gov